Cytochrome P450 and therapeutic drug monitoring with respect to clozapine

被引:55
作者
Buur-Rasmussen, B [1 ]
Brosen, K [1 ]
机构
[1] Odense Univ, Inst Publ Hlth, DK-5000 Odense C, Denmark
关键词
TDM; clozapine;
D O I
10.1016/S0924-977X(99)00033-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Clozapine is an atypical antipsychotic drug that is mainly used for the treatment of refractory schizophrenia. Clozapine is eliminated by oxidation in the liver, predominantly by cytochrome P4501A2 (CYP1A2). Due to the influence of inhibitors, inducers and genetic factors on CYP1A2-activity, several studies have reported a very large interindividual variability in clozapine plasma concentrations at a fixed dose. A number of methods have been published for the measurement of clozapine and metabolites in plasma. Plasma concentrations are most frequently measured by high-performance liquid chromatography. Most methods measure clozapine and the main metabolite, norclozapine, whereas two methods measure clozapine and two metabolites. Several studies suggest that a minimum effective clozapine plasma concentration of >350 mu g/1 must be achieved in order to ensure acceptable clinical response, whereas the upper limit of the therapeutic interval not yet has been clearly defined. The occurrence of agranulocytosis, the most serious side-effect of clozapine treatment does not seem to be dose-related and it is not possible to predict which patients are at risk of developing agranulocytosis. The risk of central nervous system side-effects seems to increase with concentrations above 1300 mu g/l. Monitoring of clozapine plasma concentrations is recommended during concomitant use of other drugs that are known to interact with the oxidation of clozapine, such as carbamazepine (inducer) or fluvoxamine (inhibitor). Overall, it is concluded that therapeutic drug monitoring may be of value in the clinical management of clozapine. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:453 / 459
页数:7
相关论文
共 70 条
[1]   CLOZAPINE - PHARMACOKINETIC INVESTIGATIONS AND BIOCHEMICAL EFFECTS IN MAN [J].
ACKENHEIL, M .
PSYCHOPHARMACOLOGY, 1989, 99 :S32-S37
[2]   Analysis of clozapine and norclozapine by high-performance liquid chromatography [J].
Akerman, KK .
JOURNAL OF CHROMATOGRAPHY B, 1997, 696 (02) :253-259
[3]   CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST [J].
BERTILSSON, L ;
CARRILLO, JA ;
DAHL, ML ;
LLERENA, A ;
ALM, C ;
BONDESSON, U ;
LINDSTROM, L ;
DELARUBIA, IR ;
RAMOS, S ;
BENITEZ, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :471-473
[4]   Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry [J].
Brosen, K .
THERAPEUTIC DRUG MONITORING, 1996, 18 (04) :393-396
[5]   FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2 [J].
BROSEN, K ;
SKJELBO, E ;
RASMUSSEN, BB ;
POULSEN, HE ;
LOFT, S .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1211-1214
[6]   CLINICAL-SIGNIFICANCE OF THE SPARTEINE-DEBRISOQUINE OXIDATION POLYMORPHISM [J].
BROSEN, K ;
GRAM, LF .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 36 (06) :537-547
[7]  
BROSEN K, 1993, NORD J PSYCHIAT S, V30, P21
[8]   HUMAN CYTOCHROME P-450PA (P-450IA2), THE PHENACETIN O-DEETHYLASE, IS PRIMARILY RESPONSIBLE FOR THE HEPATIC 3-DEMETHYLATION OF CAFFEINE AND N-OXIDATION OF CARCINOGENIC ARYLAMINES - (AROMATIC-AMINES HETEROCYCLIC AMINES CARCINOGEN METABOLISM) [J].
BUTLER, MA ;
IWASAKI, M ;
GUENGERICH, FP ;
KADLUBAR, FF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7696-7700
[9]  
CENTORRINO F, 1995, AM J PSYCHIAT, V152, P610
[10]  
CENTORRINO F, 1994, AM J PSYCHIAT, V151, P123